Precigen (PGEN) Long-Term Debt Repayments (2013 - 2023)
Precigen's (PGEN) quarterly Long-Term Debt Repayments came in at $13.9 million in Q2 2023, up 12193.81% year-on-year from N/an in Q2 2022, and down 52.63% on a QoQ basis from $29.3 million in Q1 2023.
Precigen (PGEN) Long-Term Debt Repayments (2013 - 2023) Analysis & Trends
Precigen (PGEN) has 11 years of Long-Term Debt Repayments data on file, last reported at $13.9 million in Q2 2023.
- On a quarterly basis, Long-Term Debt Repayments rose 12193.81% year-over-year to $13.9 million in Q2 2023; TTM through Mar 2024 was $13.9 million, a 92.47% decrease from a year earlier, with the FY2023 full-year figure at $43.2 million, down 72.17% from the prior year.
- Long-Term Debt Repayments for Q2 2023 stood at $13.9 million, down from $29.3 million in the prior quarter.
- Over the last five years, Long-Term Debt Repayments for PGEN reached as high as $115.7 million in Q3 2022 and fell as low as $113000.0 in Q2 2022.
- Historically, Long-Term Debt Repayments has averaged $11.1 million across 5 years, with a median of $137500.0 in 2019.
- Across the five-year window, Long-Term Debt Repayments retreated 29.9% in 2019 and surged 98817.95% in 2022, its largest moves.
- Year by year, Long-Term Debt Repayments stood at $154000.0 in 2019, then dropped by 22.08% to $120000.0 in 2020, then decreased by 4.17% to $115000.0 in 2021, then soared by 34058.26% to $39.3 million in 2022, then slumped by 64.64% to $13.9 million in 2023.
- Per Business Quant data, the three most recent Long-Term Debt Repayments figures were $13.9 million in Q2 2023, $29.3 million in Q1 2023, and $39.3 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.64 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Precigen | 1.96 Bn | 1.96 Bn | 20.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 13.89 Mn |
| Jun 30, 2023 | 13.89 Mn |
| Mar 31, 2023 | 29.33 Mn |
| Mar 31, 2023 | 29.33 Mn |
| Dec 31, 2022 | 39.28 Mn |
| Dec 31, 2022 | 39.28 Mn |
| Sep 30, 2022 | 115.73 Mn |
| Sep 30, 2022 | 115.73 Mn |
| Jun 30, 2022 | 113,000.00 |
| Jun 30, 2022 | 113,000.00 |
| Mar 31, 2022 | 164,000.00 |
| Mar 31, 2022 | 164,000.00 |
| Dec 31, 2021 | 115,000.00 |
| Dec 31, 2021 | 115,000.00 |
| Sep 30, 2021 | 117,000.00 |
| Sep 30, 2021 | 117,000.00 |
| Jun 30, 2021 | 118,000.00 |
| Jun 30, 2021 | 118,000.00 |
| Mar 31, 2021 | 116,000.00 |
| Mar 31, 2021 | 116,000.00 |